Ab&B Bio-Tech CO., LTD. JS (2627.HK)
HKSE · HKD · Healthcare · Drug Manufacturers - Specialty & Generic
HK$29.32 (-1.01%) as of
Key statistics
- Market cap
- 11.54B
- EPS (TTM)
- -0.620
- Dividend yield
- 0.00%
- 52-week range
- 28.880 – 73.000
- Revenue (TTM)
- 323.76M
- Profit margin
- -69.32%
- Volume
- 127.00k
About Ab&B Bio-Tech CO., LTD. JS
Ab&B Bio-Tech CO., LTD. JS engages in the research, development, manufacturing, and commercialization of vaccines in China. The company offers quadrivalent subunit influenza and trivalent subunit influenza vaccines. Its product pipeline also includes lyophilized human rabies, pneumococcal polysaccharide vaccine 23, and recombinant zoster vaccine which is in phase I clinical trial; and adjuvanted quadrivalent subunit influenza, adjuvanted trivalent subunit influenza, recombinant RSV, mRNA mpox, mRNA respiratory syncytial virus (RSV), pneumococcal conjugate vaccine 24, live attenuated varicella, and tetanus toxoid adsorbed vaccines which is in preclinical trial. The company was incorporated in 2015 and is headquartered in Taizhou, China.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Taizhou, China
- Employees
- 583
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.